NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Wave Life Sciences Ltd. WVE
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$42.7M
▼ 60.5% vs FY2024
EPS · FY25
$-1.21
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-56.2%
Net margin · FY25
-478.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 42.7M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 478 cents on every revenue dollar this year.
Per share
USD -1.21
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-56.2%
Return on equity, FY2025
ROE
Operating margin-504.1%
Net margin-478.3%
Return on assets-41.3%
Each USD of equity lost 56 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+127.1%
+16.3%
+75.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years+284.7%
Change, 10 years+770.8%
The share count grew 285% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 638.5M
total assets, end of FY2025
Total assetsUSD 638.5M
EquityUSD 518.4M
CashUSD 602.1M
Current ratio6.47×
Equity funds 81% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.2
−0.1
−0.1
−0.2
−0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.1
−0.2
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
·
·
·
Income tax $B
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.2
−0.1
−0.1
−0.2
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−1.21
−0.70
−0.54
−2.05
−2.36
−3.82
−5.72
−5.06
−3.85
−2.44
−1.83
−1.34
−1.90
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−56.2
−77.9
·
·
−212.1
−204.6
−282.5
−137.7
−74.4
−38.6
−24.7
·
·
Shares out B
0.19
0.15
0.12
0.09
0.06
0.05
0.03
0.03
0.03
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed